All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1300+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Business Development

Syndax Pharmaceuticals, Royalty Pharma agree on $350M royalty agreement for Niktimvo for GVHD
Monoclonal antibody, chronic graft-versus-host disease - Read more

THE GOOD
Clinical Trials

Biomed Industries touts positive topline Ph1 data for obesity hopeful NA-931
Small molecule, obesity, weight management - Read more

Atossa Therapeutics’ positive Ph2 data for (Z)-endoxifen in reducing mammographic breast density
Small molecule, breast cancer, premenopausal women with mammographic breast density - Read more

Intra-Cellular Therapies showcases positive Ph3 data for lumateperone in schizophrenia
Small molecule, schizophrenia - Read more

MannKind posts positive Ph1 data for nintedanib DPI in pulmonary fibrotic diseases
Small molecule, idiopathic pulmonary fibrosis - Read more

Sanofi’s Principia Biopharma acquisition inches closer to paying off, as rilzabrutinib Ph3 data showcases raised and sustained platelet levels
Small molecule, immune thrombocytopenia - Read more

Zealand Pharma continues jockeying for obesity supremacy, touts new Ph1 petrelinde data that demonstrates lower nausea instances compared to existing GLP-1s
Peptide, obesity - Read more

Johnson & Johnson multiple myeloma med Darzalex hits primary endpoint in Ph3
Monoclonal antibody, multiple myeloma, cancer - Read more [Paywall]

Novo Nordisk plans Ph3 for Forma Therapeutics acquired sickle cell med etavopivat
Small molecule, sickle cell disease - Read more

Abbott touts additional positive data for dissolving stent in severe peripheral artery disease
Medical device, chronic limb-threatening ischemia, severe peripheral artery disease - Read more

AstraZeneca plans pair of Ph2b trials for Eccogene licensed obesity hopeful AZD5004
GLP-1, obesity - Read more

BioCity Biopharma’s SC0062 delivers Ph2 positive data in pair of chronic kidney diseases
Small molecule, IgA nephropathy, diabetic kidney disease - Read more

Response Pharmaceuticals’ RDX-002 may contribute to reduced antipsychotic drug-induced weight gain, 20 person pilot study
Small molecule, antipsychotic-induced weight gain - Read more

PRESENTED BY YOU?
Get the attention of 1300+ Biotech & Pharma Professionals 🤩

Looking to promote your biotech/pharma/life science-focused product or service to a captivated audience of industry professionals?

Consider sponsoring TLDR Biotech - your sponsored feature would go right here!

If you want to see our prospectus or if you’re ready to work with us, just reply to this email or message me on LinkedIn.

⬇️ More Good News ⬇️

THE GOOD
Earnings & Finances

Vertex Pharmaceuticals exceeds analyst expectations in Q3 (driven by Trikafta) and reports first commercial Casgevy dose administered
Small molecule, cystic fibrosis, gene therapy, sickle cell disease, thalassemia - Read more

Supernus Pharmaceuticals posts solid YoY improvements in Q3 earnings
Small molecule, CNS disorder - Read more

THE GOOD
Fundraises

Accord Healthcare £50M ($65 million) from UK government, expanding manufacturing sites
Drug manufacturing, small molecule, injectables, public funding - Read more

PrognomiQ $34M Series D, early lung cancer detection test development
Disease detection, lung cancer, blood test, diagnostics - Read more

Inquis Medical $40M Series B, blood clot removal system
Medical device, blood clot removal, venous thromboembolism - Read more

THE GOOD
Lawsuits

Cerebral agrees to $3.7M settlement over encouraging unauthorized prescribing of Adderal and other controlled substances
Small molecule, attention deficit hyperactivity disorder - Read more [Paywall]

THE GOOD
Mergers & Acquisitions

StarFish Medical acquires Omnica, medical device design & engineering
Medical device, product design, product development - Read more

THE GOOD
Partnerships

858 Therapeutics, OpenBench enter machine learning-powered small molecule drug discovery collab
Small molecule, drug discovery, machine learning - Read more

Nxera Pharma, Antiverse collab on antibody therapeutic design for G-protein coupled receptors
Antibody, drug design, drug discovery, AI - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Approvals & Labels

Merus’ zenocutuzumab approval decision delayed by FDA, citing requiring “sufficient time” to review CMC information
Bispecific antibody, lung cancer, pancreatic ductal adenocarcinoma - Read more

Organon’s extended approval request for Vtama also faces FDA decision delay, citing ask of final dataset and long-term extension study data
Small molecule, atopic dermatitis - Read more

THE BAD
Clinical Trials

Beam Therapeutics’ first set of sickle cell disease clinical data using its “base editing” technology includes a patient death (likely due to conditioning regimen)
Base editing, sickle cell disease - Read more

Gilead, Arcellx reports three patient deaths as part of Ph2 of anito-cel in multiple myeloma
Cell therapy, multiple myeloma, cancer, CAR-T - Read more 

THE BAD
Earnings & Finances

Catalent misses expected fiscal Q1 revenue target
CDMO, contract manufacturing - Read more

Verrica Pharmaceuticals stock nearly half after Q3 results and leadership changes
Small molecule, dermatological disorders - Read more

THE BAD
Layoffs

Sana Biotechnology announces layoffs and pivots clinical focus to diabetes, lupus
Cell therapy, diabetes, lupus - Read more

THE BAD
Strategic Plans

Cellectis drops one CAR-T (UCART123) clinical asset to focus on the other two in pipeline
Cell therapy, leukemia, lymphoma, cancer, CAR-T - Read more

THE UGLY
Criminal Acts

AstraZeneca shares take a beating as alleged details emerge on spate of China-based employee criminal investigations
Insurance fraud - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here